Maria Castells, MD
Allergy & Immunology · Gardner, MANPI 1427039478
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Blueprint Medicines Corporation accounts for 67.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $19,891, more than ten times the $28 reported in 2019. Among allergy & immunology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $1414.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$44K
- Tersera Therapeutics LLC$5K
- Astrazeneca UK Limited$3K
- Sanofi$3K
- Sanofi US Services Inc.$2K
- Invivyd Inc$2K
- plus $6K from 7 others
Across 149 payments — averaging $18,644 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blueprint Medicines Corporation$2.6M
- Sanofi US Services Inc.$150K
- Bayer$7K
What the payments were for
- Consulting fees$25,20039%
- Speaking & faculty fees$36,14356%
- Travel & lodging$2,8114%
- Food & beverage$7851%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 24 | $43,832 |
| Tersera Therapeutics LLC | 8 | $4,602 |
| Astrazeneca UK Limited | 1 | $3,222 |
| Sanofi | 1 | $3,140 |
| Sanofi US Services Inc. | 3 | $2,455 |
| Invivyd Inc | 2 | $1,830 |
| Mylan Inc. | 1 | $1,680 |
| Cycle Pharmaceuticals Inc | 1 | $1,560 |
| Eisai Inc. | 1 | $1,370 |
| Daiichi Sankyo Inc. | 1 | $1,181 |
| Pfizer | 1 | $102 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $49 |
| Shire North American Group Inc | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,051 in reported general payments places this provider in the 90th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 17 | $653,463 |
| XolairOmalizumab | 41 | $129,566 |
| Dupixent SyringeDupilumab | 19 | $66,507 |
| Cromolyn Sodium | 24 | $12,475 |
| Epinephrine | 26 | $5,650 |
| Diphenhydramine Hcl | 27 | $1,468 |
| Zafirlukast | 16 | $910 |
| Hydroxyzine Hcl | 20 | $513 |
| Montelukast Sodium | 20 | $381 |
| Celecoxib | 12 | $201 |
| Levocetirizine Dihydrochloride | 11 | $59 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Blueprint Medicines CorporationAyvakit | $43,832 | $653,46317 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $1,560 | $12,47524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Gardner
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Ami MehraChelmsford$64K
- David RobertsonSpringfield$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.